169 related articles for article (PubMed ID: 7507927)
1. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor.
Seiffert D; Ciambrone G; Wagner NV; Binder BR; Loskutoff DJ
J Biol Chem; 1994 Jan; 269(4):2659-66. PubMed ID: 7507927
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin.
Deng G; Royle G; Wang S; Crain K; Loskutoff DJ
J Biol Chem; 1996 May; 271(22):12716-23. PubMed ID: 8662688
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
Preissner KT; Grulich-Henn J; Ehrlich HJ; Declerck P; Justus C; Collen D; Pannekoek H; Müller-Berghaus G
J Biol Chem; 1990 Oct; 265(30):18490-8. PubMed ID: 1698787
[TBL] [Abstract][Full Text] [Related]
4. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
5. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
6. Identification of the plasminogen activator inhibitor-1 binding heptapeptide in vitronectin.
Mimuro J; Muramatsu S; Kurano Y; Uchida Y; Ikadai H; Watanabe S; Sakata Y
Biochemistry; 1993 Mar; 32(9):2314-20. PubMed ID: 7680229
[TBL] [Abstract][Full Text] [Related]
7. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
van Meijer M; Gebbink RK; Preissner KT; Pannekoek H
FEBS Lett; 1994 Oct; 352(3):342-6. PubMed ID: 7523190
[TBL] [Abstract][Full Text] [Related]
8. The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Kamikubo Y; Kroon G; Curriden SA; Dyson HJ; Loskutoff DJ
Biochemistry; 2006 Mar; 45(10):3297-306. PubMed ID: 16519524
[TBL] [Abstract][Full Text] [Related]
9. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
10. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
[TBL] [Abstract][Full Text] [Related]
11. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.
Seiffert D; Loskutoff DJ
J Biol Chem; 1991 Feb; 266(5):2824-30. PubMed ID: 1704366
[TBL] [Abstract][Full Text] [Related]
12. Copper(II) Ions Increase Plasminogen Activator Inhibitor Type 1 Dynamics in Key Structural Regions That Govern Stability.
Bucci JC; Trelle MB; McClintock CS; Qureshi T; Jørgensen TJ; Peterson CB
Biochemistry; 2016 Aug; 55(31):4386-98. PubMed ID: 27416303
[TBL] [Abstract][Full Text] [Related]
13. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
Padmanabhan J; Sane DC
Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the interaction between vitronectin and the urokinase receptor.
Okumura Y; Kamikubo Y; Curriden SA; Wang J; Kiwada T; Futaki S; Kitagawa K; Loskutoff DJ
J Biol Chem; 2002 Mar; 277(11):9395-404. PubMed ID: 11773078
[TBL] [Abstract][Full Text] [Related]
15. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.
Jensen JK; Durand MK; Skeldal S; Dupont DM; Bødker JS; Wind T; Andreasen PA
FEBS Lett; 2004 Jan; 556(1-3):175-9. PubMed ID: 14706846
[TBL] [Abstract][Full Text] [Related]
16. Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface.
Podor TJ; Singh D; Chindemi P; Foulon DM; McKelvie R; Weitz JI; Austin R; Boudreau G; Davies R
J Biol Chem; 2002 Mar; 277(9):7529-39. PubMed ID: 11744725
[TBL] [Abstract][Full Text] [Related]
17. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
Lawrence DA; Berkenpas MB; Palaniappan S; Ginsburg D
J Biol Chem; 1994 May; 269(21):15223-8. PubMed ID: 7515053
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis.
Lawrence DA; Palaniappan S; Stefansson S; Olson ST; Francis-Chmura AM; Shore JD; Ginsburg D
J Biol Chem; 1997 Mar; 272(12):7676-80. PubMed ID: 9065424
[TBL] [Abstract][Full Text] [Related]
19. A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity.
Schar CR; Blouse GE; Minor KH; Peterson CB
J Biol Chem; 2008 Apr; 283(16):10297-309. PubMed ID: 18174166
[TBL] [Abstract][Full Text] [Related]
20. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
